Sign in
Not yet recruitingPhase 1

Alpha-0261 tablets for chronic spontaneous urticaria and effect of food in healthy adults

Tests Alpha-0261 tablets in adults with chronic spontaneous urticaria and healthy volunteers.

Key facts

Who runs it
AlphaMol Science Ltd. (Shanghai)
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
Status
Not yet recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
1 Jul 2026
Expected to end
30 Jun 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Alpha-0261
  • Placebo
Record updated
6 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic spontaneous urticaria (long-lasting hives with no known trigger) for Part 1. It is also looking for healthy adults for Part 2, which tests the effect of food.

Age
Part 1: 18 to 75 years. Part 2: 18 to 55 years.
Sex
Men and women can join.
Disease stage
Part 1: chronic spontaneous urticaria diagnosed at least 6 months before screening. Part 2: in general good health, weight ≥ 50 kg (110 lb) for men and ≥ 45 kg (99 lb) for women, BMI 19 kg/m2 to 28 kg/m2.
Earlier treatment
Part 1: stable second-generation H1 antihistamine therapy for at least 2 weeks before randomization. People must be willing to keep it unchanged during the study.

Main reasons for not taking part

  • Part 1: hives with a clear trigger, such as cold, heat, sun, pressure, water, sweating or scratching the skin.
  • Part 1: other long-lasting itchy skin diseases, such as atopic dermatitis or psoriasis.
  • Part 1: other conditions that can cause hives or swelling, such as urticarial vasculitis, mastocytosis or drug-induced urticaria.
  • Part 2: any past severe allergic reaction or anaphylaxis.
  • Part 2: clearly abnormal lab test results.

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Written informed consent must be obtained before any assessment is performed.(Part 1 and Part 2)
  • Aged ≥ 18 and ≤ 75, male or female (Part 1)
  • Diagnosed with CSU prior to screening at least 6 months. (Part 1)
  • Received stable second-generation H1 antihistamine therapy for at least 2 weeks before randomization, and is willing to maintain the stable treatment regimen throughout the study treatment period. (Part 1)
  • Aged ≥ 18 and ≤ 55, male or female (Part 2)
  • Weight: ≥ 50 kg for males, ≥ 45 kg for females; 19 kg/m2 ≤ body mass index (BMI) ≤ 28 kg/m2. (Part 2)
  • In general good health. (Part 2)

Who cannot take part

  • Other chronic pruritic skin diseases that may affect the assessment of study outcomes, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or psoriasis. (Part 1)
  • Other conditions that may cause urticaria or angioedema symptoms, including but not limited to urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or acquired/drug-induced urticaria. (Part 1)
  • Have a history of any severe allergic reaction or anaphylaxis. (Part 2)
  • Any condition, which in the investigator's opinion might jeopardize articipant's safety or compliance with the protocol. (Part 2)
  • Have clinically significant abnormalities on clinical laboratory results. (Part 2)
  • Inducible urticaria with identifiable triggers, including dermographism, cold contact urticaria, heat contact urticaria, solar urticaria, pressure urticaria, delayed pressure urticaria, aquagenic urticaria, cholinergic urticaria, or contact urticaria. (Part 1)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Alpha-0261 Tablets in healthy Chinese adults and in patients with chronic spontaneous urticaria.

The 3 groups in the trial

  • Multiple Ascending Dose (Part 1)Treatment being tested

    50 mg (25 mg tablet), 125 mg (125 mg tablet), 250 mg (125 mg tablet), and 500 mg (125 mg tablet) of Alpha-0261 will be administered QD for 4 weeks, orally to subjects in the treatment group, cohort 1 to 4.

    Treatment: Alpha-0261

  • Placebo (Part 1)Placebo, for comparison

    Matched placebo control of cohort 1 to 4.

    Treatment: Placebo

  • Single Dose (Part 2)Treatment being tested

    Single Dose of Alpha-0261. Alpha-0261 is administered once per treatment cycle. Two treatment cycles.

    Treatment: Alpha-0261

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Food in Healthy Participants.
Plain-language title
Alpha-0261 tablets for chronic spontaneous urticaria and effect of food in healthy adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07684560, who can take part
Record updated
6 July 2026